{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of a Novel Surgical Technique for ec-LVAD Implantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial was conducted at a single surgical center."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were patients with refractory cardiogenic shock and no available typical outflow cannula insertion site."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received the novel ec-LVAD implantation technique, while the control group received standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate a new surgical technique for implanting an extracorporeal left ventricular assist device (ec-LVAD) in patients with refractory cardiogenic shock."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was successful weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) within 15 days post-implantation."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not feasible due to the nature of the intervention."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 20 participants were randomised, with 10 in each group."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intervention group, 8/10 (80%) were successfully weaned from VA-ECMO compared to 4/10 (40%) in the control group (p = 0.04)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "In the intervention group, 8/10 (80%) were successfully weaned from VA-ECMO compared to 4/10 (40%) in the control group (p = 0.04)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included mild transvalvular regurgitation in 2/10 (20%) of the intervention group and nonocclusive mesenteric ischemia in 1/10 (10%)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: This study was funded by the National Institute of Health."
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}